Type 1 diabetes vaccine passes Phase 1 clinical trial

Bacillus Calmette-Guerin, a vaccine that could reverse Type 1 diabetes, has passed a Phase 1 clinical trial.

The first clinical trials for Bacillus Calmette-Guerin show that it may reverse Type 1 diabetes. The Phase 1 clinical trial revealed the vaccine to be safe and effective. A Phase II trial is currently being planned by scientists from Massachusetts General Hospital and the Iacocca Foundation.

"We are making great progress and are really excited to be able to move this potential treatment to the next stage of clinical testing," Denise Faustman, director of the Immunobiology Laboratory at MGH and an associate professor of Medicine at Harvard Medical School, told

The Bacillus Calmette-Guerin vaccine works by temporarily raising the levels of tumor necrosis factor in humans and mice. These increased levels eliminate abnormal white cells in individuals with Type 1 diabetes, which causes a reversal of the disease.

Currently, there is no cure for Type 1 diabetes, which occurs when cells of the pancreas that produce insulin are attacked by the body's own immune system. Type 1 diabetes is treated by controlling the disease's symptoms. Young people under the age of 20 are primarily affected by Type 1 diabetes, though it can occur at any age.